Solid Biosciences Inc. (SLDB) Stock

Solid Biosciences Inc. (SLDB) is a Healthcare stock trading at $9.09 (as of 2026-08-20), with a market capitalization of $894.91M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Understand Solid Biosciences Inc.: how it makes money

Solid Biosciences develops gene transfer therapies for Duchenne muscular dystrophy, with lead candidates SGT-001 (a Phase I/II program) and SGT-003, and it also builds related gene transfer platform technologies, with revenue generated from collaborations.

Because the company is still running clinical-stage gene therapy programs (SGT-001 Phase I/II, plus SGT-003), near-term economics are structurally driven by collaboration revenue timing and the pace of clinical progress, while operating results can remain heavily loss-making until therapies advance.

Revenue by segment (latest quarter)
Collab	$0.0B

Business quality (Weak): Clinical-stage biotech with measurable early program execution (INSPIRE dosing and sites), but very limited collaboration revenue and a deeply negative operating margin indicate profitability is not yet supported by product sales.

Bull case

Trackable clinical execution in the INSPIRE trial: In the latest quarter, 23 Duchenne INSPIRE trial participants were dosed across 15 INSPIRE trial sites.
Commercial signal via collaborations: The company recorded Collaboration Revenue (0.01 USD_B in the provided period), which can indicate ongoing external validation and support.

Bear case

Profitability remains structurally challenged: Operating margin is reported as -2776.6% for the provided period, consistent with heavy ongoing losses for a clinical-stage company.
Early-stage dependence on trial outcomes: The lead program (SGT-001) is in Phase I/II, so future progress depends on clinical results and continuation, not on established product revenue.

Valuation — source: SEC EDGAR (first-party)
Price	$9.09
Market Cap	$894.91M
Price / Book	2.39
Price / Sales	90.25
FCF Yield	-28.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$9.90M
Net Margin	-1760.1%
Revenue Growth (YoY)	4.6%
EPS Growth (YoY)	-35.0%
FCF Growth (YoY)	56.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.84 (grey)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	PERCEPTIVE ADVISORS LLC ($85.73M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Alexander G. Cumbo
Employees	100
Country	US
IPO Date	2018-01-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.